clinical trial · NCT06890884
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Merck Sharp & Dohme LLC·phase2·recruiting·n = 594
Lymphoma, Large B-Cell, DiffuseZilovertamab vedotinRituximabCyclophosphamideDoxorubicinRituximab BiosimilarPrednisonePrednisolonePolatuzumab vedotin
brief summary
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing. The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.
started
Apr 11, 2025
primary completion
Dec 13, 2027
completion
Dec 16, 2032
last updated
Jun 8, 2026
official title
A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol